NR4A1 and triple-negative breast carcinoma: Although immunotherapy has shown promising results in the treatment of certain breast cancer subtypes, such as triple negative breast cancer, its efficacy in hormone receptor-positive subtypes, such as hormone receptor+/HER2−, remains limited.